Kademani Anvvi, Avraam Constantinos, Montenegro Daniel, Paloh Ansu, Somannagari Nethra, Gupta Aarushi, Lafi Ali W, Algaba Alonso E, Islam Rabeeul, Fahima Cheeranthodika, Siddiqui Humza F
Medicine, Balagangadharanatha Swamiji (BGS) Global Institute of Medical Sciences, Bangalore, IND.
Neurosurgery, Nicosia General Hospital, Strovolos, CYP.
Cureus. 2025 Aug 8;17(8):e89629. doi: 10.7759/cureus.89629. eCollection 2025 Aug.
Neurodegenerative diseases and spinal cord injuries (SCI) pose a significant burden on the healthcare system globally. Diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease precipitate cognitive, motor, and behavioral deficits. Parallelly, spinal cord injuries produce sensory and motor deficits, which are burdensome psychologically, socially, and economically. Current management strategies focus only on symptomatic relief, with no definitive cure. Stem cells have been explored for regenerative therapy. This review focuses on developments, limitations, and future potential of stem cell therapy. Stem cells affect the central nervous system via neuroprotective mechanisms, immunomodulatory effects, and mitigation of oxidative stress. The clinical implications of stem cell therapy in treating neurodegenerative diseases and SCI are debatable due to varied outcomes. Challenges related to sample size, long-term follow-up, and assessment of adverse effects should be mitigated in future research. Researchers are currently exploring optimal stem cell types along with various transplantation strategies. Biomaterials integrated with stem cells are a novel approach for treating neurodegenerative diseases and spinal cord injuries. Certain genetic modifications have shown improved results. Screening patients to ascertain better responses to therapy has proven to be a challenge. Other complications include graft vs. host reaction and degeneration of transplanted neurons due to pathogenesis and tumorigenesis. However, the majority of the potential stem cell therapeutic avenues are in the preclinical stage and are being tested on animal models. Guidelines pertaining to ethical concerns and regulatory frameworks need to be established to unfold the full potential of stem cell therapy in the clinical setting. Recent advances also show an increased need to formulate patient-specific approaches to treatment, ranging from stem cell selection to the technique of transplantation. Ongoing clinical trials can address the current challenges and leverage emerging technologies, leading to definitive treatments for neurodegenerative diseases and spinal cord injuries.
神经退行性疾病和脊髓损伤(SCI)给全球医疗保健系统带来了沉重负担。阿尔茨海默病、帕金森病、肌萎缩侧索硬化症和亨廷顿舞蹈病等疾病会引发认知、运动和行为缺陷。与此同时,脊髓损伤会导致感觉和运动缺陷,在心理、社会和经济方面都是沉重负担。目前的治疗策略仅侧重于症状缓解,尚无根治方法。人们已探索将干细胞用于再生治疗。本综述重点关注干细胞治疗的进展、局限性及未来潜力。干细胞通过神经保护机制、免疫调节作用和减轻氧化应激来影响中枢神经系统。由于结果各异,干细胞治疗在治疗神经退行性疾病和脊髓损伤方面的临床意义存在争议。未来研究应减轻与样本量、长期随访及不良反应评估相关的挑战。研究人员目前正在探索最佳的干细胞类型以及各种移植策略。与干细胞整合的生物材料是治疗神经退行性疾病和脊髓损伤的一种新方法。某些基因修饰已显示出更好的效果。事实证明,筛选患者以确定对治疗的更好反应是一项挑战。其他并发症包括移植物抗宿主反应以及由于发病机制和肿瘤发生导致的移植神经元退化。然而,大多数潜在的干细胞治疗途径仍处于临床前阶段,正在动物模型上进行测试。需要建立有关伦理问题和监管框架的指导方针,以在临床环境中充分发挥干细胞治疗的潜力。最近的进展还表明,越来越需要制定针对患者的治疗方法,从干细胞选择到移植技术。正在进行的临床试验可以应对当前的挑战并利用新兴技术,从而为神经退行性疾病和脊髓损伤带来确定性的治疗方法。